| Literature DB >> 20307219 |
Andrea L Harzstark1, Eric J Small.
Abstract
IMPORTANCE OF THE FIELD: Castrate-resistant prostate cancer continues to be inadequately addressed by currently available therapies. AREAS COVERED IN THIS REVIEW: This review will discuss recent developments, including new chemotherapies and chemotherapy regimens, antiangiogenic therapy, immunotherapy, and other new agents, such as endothelin-A receptor antagonists and clusterin inhibitors. WHAT THE READER WILL GAIN: The reader will gain an understanding of the therapies in development for castration-resistant disease. TAKE HOME MESSAGE: Therapies focused on multiple different targets are currently being studied for castrate-resistant prostate cancer.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20307219 DOI： 10.1517/14656561003677382
Source DB: PubMed Journal: Expert Opin Pharmacother ISSN： 1465-6566 Impact factor: 3.889